CSPG4 IgE treatment restricted tumor growth or improved survival across distinct in vivo models, irrespective of the tumor site, and with engraftment of immune cells from either healthy volunteers or patients (Fig. 9). This evidence concerns the gene CSPG4 and neoplasm.